Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

EXCHANGE LISTING, LLC ADVISES HEARTBEAM INC. AND SECURES NASDAQ LISTING

Exchange Listing

Exchange Listing, LLC has finalized the Nasdaq Capital Markets listing for its client, Heartbeam Inc. (“ HeartBeam ” or the “Company”) (Nasdaq: BEAT and BEATW) on November 11 2021. The emerging digital healthcare company’s common stock began trading on the Nasdaq exchange under the symbols BEAT and BEATW, respectively. Concurrent with the NASDAQ listing, HeartBeam announced the pricing of its underwritten initial public offering of 2,750,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $6.00 The warrants have an exercise price of $6.00 per share and are exercisable for a period of five years after the issuance date. All units are being offered by HeartBeam, Inc. In addition, HeartBeam has granted the underwriters a 30-day option to purchase an additional 412,500 shares of its common stock and/or warrants to purchase up to an additional 412,500 of its common stock, at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds to HeartBeam from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $16.5 million. The Benchmark Company acted as the sole book-running managers for the offering. The Company, based in Santa Clara, California is a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, “Working with Exchange Listing as IPO counsel put us in a winning position,” commented Branislav Vajdic, CEO, HeartBeam. “Their exemplary team put us in contact with a best in class investment banker and legal team. We are thrilled to now be listed on the Nasdaq Capital Markets.” “When we met the HeartBeam management team, and reviewed their innovative digital healthcare products, we became incredibly enthusiastic about their market potential,” explains Peter Goldstein, Chief Executive Officer of Exchange Listing. “ HeartBeam’s medical grade heart attack detection technology is a game changer, allowing patients to determine if they are having a life threatening medical event. In concert with HeartBeam’s management and bankers, the Company now has a listing on Nasdaq Capital Markets.” Exchange Listing provides companies with cost-effective and efficient direct access to one-stop solutions in the strategic planning and implementation of listing and uplisting on senior exchanges such as the Nasdaq or NYSE. Focusing on company-specific structuring to meet listing requirements, Exchange Listing serves as the primary point of contact with the exchange, investment bankers and lawyers throughout the listing process. With extensive experience in investment banking, securities law, corporate governance and business management, Exchange Listing and its strategic partners facilitate clients' listing and capital markets objectives. About Exchange Listing Exchange Listing provides growth companies with direct access to a one-stop solution in the strategic planning and implementation of listing on a senior exchange such as NASDAQ or NYSE in a cost effective and efficient process. We assist clients in going public whether through an initial public offering, listing from another marketplace, merger or direct offering. We serve as the primary point of contact with the exchange, investment bankers, lawyers and other service providers. Our founders, strategic partners and advisors are entrepreneurs with backgrounds in investment banking, securities law, corporate governance and business management and have served as officers and directors of public and private companies. We pride ourselves in taking a hands-on role with our clients throughout the listing process. For more information, please visit: www.exchangelistingllc.com or contact info@exchangelistingllc.com. Contact Details Julie Livingston +1 347-239-0249 julie@wantleverage.com Company Website https://exchangelistingllc.com/

November 15, 2021 01:17 PM Eastern Standard Time

Doseology Set to Trade CSE: MOOD

Doseology Sciences Inc.

Doseology Sciences Inc. (CSE: MOOD ) (“ Doseology ” or the “ Company ”) is pleased to announce that its shares will begin trading on the CSE today and has retained Hybrid Financial Ltd. (“ Hybrid ”) to provide marketing and call centre services to the Company. Hybrid has agreed to comply with all applicable securities laws and the policies of the Canadian Securities Exchange (the “ CSE ”) in providing their services. Hybrid has been engaged by the Company for an initial period of six (6) months starting from November 15, 2021 (the “ Initial Term ”) and shall be renewed for an additional six (6) months thereafter, unless terminated by the Company in accordance with the Agreement. Hybrid will be paid a monthly fee of $22,500 plus applicable taxes, during the Initial Term. Daniel Vice, CEO and Director commented, “We look forward to Hybrid amplifying market awareness to the Doseology brand and broadening the Company’s reach within the investment community”. No securities regulatory authority has either approved or disapproved of the contents of this news release. The units have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the Units may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Doseology in any jurisdiction in which such offer, solicitation or sale would be unlawful. On Behalf of the Board of Directors Doseology Sciences Inc. Daniel Vice Chief Executive Officer and Director About Doseology Sciences Inc. Doseology is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health. About Hybrid Financial Ltd. Hybrid is a sales and distribution company that actively connects issuers to the investment community across North America. Using a data driven approach, Hybrid provides its clients with comprehensive coverage of both American and Canadian markets, Hybrid Financial offices in Toronto, and Montreal. FOR FURTHER INFORMATION CONTACT: Investor Relations Email: investor@doseology.com Telephone: 236-349-0064 Website: www.doseology.com Forward Looking Statements This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Contact Details Investor Relations +1 236-349-0064 investor@doseology.com

November 15, 2021 08:00 AM Eastern Standard Time

Doseology Receives Receipt for Final Prospectus and Announces Listing on the CSE

Doseology Sciences Inc.

NOT FOR DISTRIBUTION IN THE UNITED STATES OR DISSEMINATION IN THE UNITED STATES Doseology Sciences Inc. (“ Doseology ” or the “ Company ”), a diversified life sciences company, is pleased to announce that it has obtained a receipt for its final non-offering, long form prospectus dated October 29, 2021 from the British Columbia Securities Commission. Concurrent with its prospectus filing, the Company also received approval from the Canadian Securities Exchange (the “ CSE ”) to list the Company’s common shares on the CSE. The approval results in the Company’s previously issued 11,885,000 Subscription Receipts (aggregate gross proceeds of $2,377,000) to be automatically converted, without further payment, into 5,942,500 units. Each unit is comprised of one common share (a “ Share ”) and one common share purchase warrant (a “ Warrant ”) with each Warrant exercisable into one Share at a price of $0.80 per Share for a period of 24 months. The Company may elect, at its option, to accelerate the expiry date of the Warrants to a date that is 30 days from the date of notice to the Warrant holders if the closing price of the Shares on the CSE is equal to or greater than $1.40 for 20 consecutive trading days. The common shares of the Company will commence trading on the CSE on Monday, November 15, 2021 under the symbol “ MOOD ”. Daniel Vice, CEO of Doseology, commented “We are thrilled to finally obtain our listing on the CSE and are appreciative of the significant efforts of our team, our advisors, and the exchange to get to the finish line”. Mr. Vice further commented, “We now look forward to significantly accelerate the development of our ambitious business plan, through organic growth, partnerships, joint ventures and acquisitions“. No securities regulatory authority has either approved or disapproved of the contents of this news release. The units have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the Units may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Doseology in any jurisdiction in which such offer, solicitation or sale would be unlawful. On Behalf of the Board of Directors Doseology Sciences Inc. Daniel Vice Chief Executive Officer and Director ABOUT DOSEOLOGY (CSE: MOOD) Doseology is a BC-based company on a mission to restore mental health through establishing psychedelic-assisted therapy clinics, building a library of intellectual property through research on psychedelic compounds, and the development and sale of its branded functional mushroom products. The Company has filed an application with Health Canada to become a “Licensed Dealer” under the Controlled Drugs and Substances Act (Canada) which would permit the laboratory analysis of psilocybin and psilocin from mushrooms, as well as the possession, processing, sale, sending, transportation and delivery of Psychedelic Compounds. FOR FURTHER INFORMATION CONTACT: Investor Relations Email: investor@doseology.com Telephone: 236-349-0064 Website: www.doseology.com Forward Looking Statements This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Contact Details Investor Relations +1 236-349-0064 investor@doseology.com

November 12, 2021 06:21 PM Eastern Standard Time

iHealth to Demo New COVID-19 In-Home Rapid Test

ShowStoppers and Keiretsu Forum Southern California

iHealth will introduce and demo its new in-home COVID-19 Antigen Rapid Test, with results in 15 minutes, just authorized by the FDA under an Emergency Use Authorization, to journalists attending a live stream of ShowStoppers TV ( https://www.showstoppers.com ) scheduled for today, Friday, 12 Nov. 2021. Journalists and potential investors will also discover 12 startups with healthtech tools, cannabis platforms, fuels that reduce pollution, tech to make lithium batteries safer, and more -- companies mentored by Keiretsu Forum Southern California ( https://www.k4Socal.com ). The press conference streams live, online, beginning today at Noon Eastern, continuing to 330 pm Eastern. To register to attend, journalists may contact Steve Leon, partner, ShowStoppers, sl@showstoppers.com. This is the first joint event organized by ShowStoppers and Keiretsu Socal. ShowStoppers ® announced in late October it is partnering with Keiretsu SoCal to help journalists discover startups mentored and funded by the community of accredited private-equity and angel investors, venture capitalists, corporate and institutional investors, incubators, business leaders, entrepreneurs and universities. Keiretsu SoCal is a region within Keiretsu Forum, a worldwide network of 3,000 investors organized into 60 chapters on 3 continents with capital, technology, talent, resources and deal flow that to date has invested more than $1B USD into companies – including a record 314 fundings into seed, early-stage and late-stage companies during 2020, led by life science, healthcare and medical devices, consumer products, and environmental and emerging technologies. The Southern California region of Keiretsu Forum comprises four chapters in San Diego, Westlake Village, Los Angeles and Orange County. The presenting startups include: BOMANI, maker of Cold Buzz, an award-winning alcohol-infused cold brew coffee that has earned shelf space at Ralph’s, Whole Foods, Total Wine, Stater Bros. Crafty Elk ® -- named the world’s first ‘Smart Alcohol’ by the Huffington Post. smallTalk™ -- a consumer technology startup that just launched the smallTalk Egg, the first in a line of IoT products that enable parents to introduce children to foreign languages through play, starting in infancy and preschool. Soteria -- enabling a world where lithium-ion batteries and the devices they power are inherently safe. Supported by an open-innovation consortium with over 100 active partners, including NASA, Mercedes-Benz, Motorola, Lenovo, Bosch, DuPont, Applied Materials. StressFree TC -- processing 4-5 times more real estate files than a human, saving agents and brokers thousands of dollars and hundreds of hours of time. Genetica -- leveraging machine learning, natural language processing, AI and data science to build a cannabis platform that identifies the provenance and efficacy of what is grown, bought, sold and consumed. Trillion -- entering the sea-trial stage with one of the largest cruise line corporations of ESG fuels (Environmental, Social and Governance) that are up to 90% more effective in reducing engine pollution, and 15% more fuel efficient. Perfect Point EDM -- designing solutions for Aerospace's most-overlooked problems. InControl Medical -- designs and manufactures patented devices for the control of incontinence. Inhalio -- agreements with Philips/Lumileds and Acqua Di Parma to license and integrate the Digital Scent 3.0 Platform in the IoT Automotive and Home markets. Inmedix -- an innovative cloud platform that predicted rheumatoid arthritis (RA) treatment outcome a year in advance and guided increased RA remission from 25% to 79%. Orion Biotechnology -- a proprietary drug discovery platform to grow a pipeline of high value drug candidates and unlock therapeutics. “Entrepreneurs need more than funding,” said Connie Harrell, Regional President, Keiretsu Forum So Cal. “They also need exposure with the press, marketing and promotions, to create a generous return for the investors who mentor and fund those entrepreneurs – which begins with this press conference, streaming online, live, powered by ShowStoppers.” About ShowStoppers Now in its 26th year, ShowStoppers, https://www.showstoppers.com, is the global leader in producing press and business events spanning the U.S., Europe and Asia. Each event organizes product launches, sneak previews and demonstrations for selected journalists, bloggers, industry and financial analysts, venture capitalists and business executives. Industry leaders, innovators and startups exhibit to generate news coverage and product reviews, make new connections, promote brand and open new markets. ShowStoppers produces official press events at CE Week, IFA and NAB; partners with CTA, IFA, GSMA and CEATEC; and produces events during CES, IFA, MWC, NAB, CE Week, CEATEC and other tradeshows. ShowStoppers streams online, broadcasting live events, month after month. To learn more about how you and your company can meet the press at ShowStoppers press events in person and online at ShowStoppers TV, contact Lauren Merel, lauren@showstoppers.com, +1 908-692-6068, or Dave Leon, dave@showstoppers.com, +1 845-821-6123. Contact Details For press registration, please contact Steve Leon +1 310-936-8530 sl@showstoppers.com For Keiretsu Forum Southern California, please contact Cindy Fraley +1 949-899-4849 hello@k4socal.com

November 12, 2021 09:00 AM Eastern Standard Time

Healthcare Industry’s First Carbon Tech Platform Launched by Zasti

Zasti

Zasti, an advanced analytics enterprise that offers carbon tech solutions and strong environmental, social, and governance (ESG) values to the United States healthcare marketplace, announced it is collaborating with Change Healthcare (NASDAQ: CHNG), a health care technology leader. The two companies are aiming to build efficiencies and reduce carbon emissions generated by the healthcare industry. Combining billions of data points from Change Healthcare with Zasti’s AI technology allows users to Assess, Target, Optimize, and Monitor ( ATOM TM ) carbon emissions. “Working with Change Healthcare to deploy ATOM throughout the healthcare industry will allow organizations to be more efficient as decarbonization strategies are considered and implemented” explained Krish R. Krishnan, Zasti’s CEO. “The healthcare industry is responsible for a tenth of all greenhouse gas emissions, making it a focal point for stakeholder scrutiny”. Zasti’s ATOM provides precise measurement of direct and indirect carbon emissions via a proprietary healthcare carbon database. With this data, carbon emission hotspots are identified using pre-designed algorithms providing uses with an AI-driven decarbonization strategy. “The power of our collaboration is combining real-world data that is already processed by Change Healthcare with Zasti’s ATOM platform,” said Tim Suther, senior vice president and general manager of Data Solutions at Change Healthcare. “A provider’s carbon baseline can be quickly established with visibility into how individual procedures and activities contribute to carbon emissions. The ATOM platform then provides benchmarks and actionable insights to reduce those emissions. Real-time data-driven actions can then facilitate carbon emission reductions.” Zasti’s ATOM AI technology offers solutions that achieve continuous optimization and offsetting of carbon emissions. It also tracks the real-time progress of emission reductions through a user-friendly dashboard that integrates with accounting, sustainability, and disclosure details. Dr. David Chang, leading cataract surgeon at the Peninsula Eye Surgery Center in Northern California shared his perspective by stating, “The carbon footprint of the healthcare sector in general, and the operating room in particular, is surprisingly large. We have an important opportunity to make an impact by being more green and by reducing needless OR waste.” “Like all industries today, healthcare too must accelerate the decarbonization process. No industry, especially healthcare, is immune from the responsibility to strive for achieving net-zero emissions. Nor can an industry dodge the looming regulations imposing a plan and the actions moving toward net-zero emissions”, Krishnan, also a Delegate to COP26, stated. “Our collaboration with Change Healthcare is a major step in revolutionizing the healthcare industry by making it sustainable.” About Zasti The Zasti proprietary carbon emission metrics database and AI platform offer a granular, accurate baselining of emission and configurable ESG (Environmental, Social, & Governance) compliance reports. The Zasti AI analytics suite provides management teams with fact-based, real-time, actionable insights that deliver meaningful progress toward meeting decarbonization goals. To automate your decarbonization goals, visit https://www.zasti.ai/ ### For more information or to schedule an interview with Krish Krishnan, contact Dan Rene at 202-329-8357 or daniel.rene@kglobal.com. Contact Details kglobal Dan Rene +1 202-329-8357 daniel.rene@kglobal.com Company Website https://zasti.ai/

November 11, 2021 10:00 AM Eastern Standard Time

BIOSAPIEN CLOSES $1.8M SEED ROUND LED BY SOSV & HIKMA VENTURES

Biosapien

BioSapien, a biotech company has announced it has raised $1.8M in seed round funding led by global venture capital investor SOSV. Co-investors in the round include Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, Side Door Ventures, and other high-net worth angels and investors (Additional investors listed below*). In addition to the seed round funding, a non-dilutive grant of $256K from the National Science Foundation will accelerate the development of BioSapien’s patented product, MediChip ™: a 3D printed biodegradable mesh chip designed to deliver cancer drugs directly to the tumor site while reducing side effects. “It’s great to have the support of these esteemed investors in BioSapien,” says Dr. Khatija Ali, CEO and co-founder of BioSapien. “The seed round funds will advance development of MediChip ™ and give access to global distribution channels and manufacturing. Chemotherapy can cause devastating side effects for patients. MediChip ™ is designed to deliver cancer drugs straight to hard-to-reach tumor sites, for increased efficacy with reduced toxicity.” MediChip ™ is a novel biodegradable drug delivery platform designed to precisely administer any type of FDA-approved drug, locally and in a sustained manner. Pre-clinical research shows that in comparison to systemic chemotherapy, MediChip ™ mitigates systemic side-effects through localized controlled release. For cancer indications, it has the potential to improve the patient’s quality of care and life. It is designed to be a first-line treatment option for stage III locally advanced gastrointestinal cancer patients during surgery for adjuvant chemotherapy delivery. MediChip ™ was granted its patent in February 2021 with a priority date of December 21, 2018. Potential For Stage III, IV Pancreatic Cancer The current clinical pipeline includes BioSapien’s lead indication of pancreatic cancer and others including lung cancer, esophageal cancer, and colorectal cancer. There are approximately 57,000 new cases of pancreatic cancer in the US every year. Founded in 2018, in New York City, NY, BioSapien has already garnered global attention. In addition to the seed round funding and NSF grant which Inspiralia assisted in securing, BioSapien has been recognized in high profile biotech pitch competitions, winning the Pitch Night by Amazon and the Get in the Ring Start Up Competition. The company is currently a semi-finalist in the PacBio 2021 conference. Now, with backing from SOSV, Hikma, and JPIN VCATS, MediChip ™ has strategic partners, financial backing, and global reach to progress towards achieving the goal of impacting patient care worldwide. * Additional investors include; SOSV, Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, Side Door Ventures, Harbr, Beni VC, Cedas Foundation, Kartik Garg - The Modern Nomad, George and Saul, and other angels About BioSapien BioSapien Inc. is a venture-backed biotechnology company focused on innovative therapies to transform patient care. The company invented MediChip ™: a patented treatment that early research has shown can reduce the system-wide side effects of cancer chemotherapy treatments. The 3D printed biodegradable mesh is designed to allow for a more exact delivery of already approved FDA pharmaceuticals without the adverse effects. For more information, visit www.biosapien.com. About SOSV SOSV is a global venture capital firm headquartered in Princeton, NJ. The firm has more $900 million in assets under management and more than 1,000 portfolio companies. SOSV operates the startup development programs HAX (hard tech), IndieBio (life sciences), Chinaccelerator and MOX (cross-border growth in Asia) and dlab (blockchain). Sean O'Sullivan, a serial entrepreneur and technologist, is the founder of SOSV. The firm has 8 general partners and a 130-person staff across seven locations in the US, Europe and Asia. About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, Hikma has been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, Hikma is a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and uses their unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. Hikma is committed to their customers, and the people they care for, and by thinking creatively and acting practically, Hikma provides them with a broad range of branded and non-branded generic medicines. Together, Hikma’s 8,600 colleagues are helping to shape a healthier world that enriches everyone’s communities. Hikma is a leading licensing partner, and through their venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com. About Hikma Ventures Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company. For more information, please visit www.hikmaventures.com. About Biosapien Biosapien Inc. is a venture-backed biotechnology company focused on innovative therapies to transform patient care. The company developed MediChip ®: a patented treatment that reduces the system-wide side effects of cancer chemotherapy treatments. The 3D printed biodegradable mesh allows for a more exact delivery of already approved FDA pharmaceuticals without the adverse effects Contact Details WantLeverage Communications Julie Livingston +1 347-239-0249 julie@wantleverage.com Company Website https://biosapien.com/

November 11, 2021 08:03 AM Eastern Standard Time

Powering Through a Sore Throat: Understanding the Symptoms and Seeking Relief

YourUpdateTV

From a first date to a big audition, to an important presentation, having a sore throat can easily put a damper on important moments and your everyday life. Recently, Family Medicine Physician, Dr. Jennifer Caudle, teamed with Mucinex and YourUpdateTV on a satellite media tour to discuss how to relieve sore throat symptoms. With another cold and flu season upon us, we know the impact of symptoms like cough, body aches, fever and more can really impede on our everyday lives. Recent findings show that sore throat pain is one of the top three most debilitating symptoms alongside fever and migraine. To better understand the impact sore throat pain has on people’s lives, Mucinex surveyed 2,005 U.S. adults in partnership with One Poll* about their experiences coping with it. Despite this, 55% of people are most likely to “power through” a sore throat—meaning they would continue working, going to school, running errands, completing housework, etc. while dealing with difficult sore throat pain. While cold and flu season can be so unpredictable each year, there are many over-the-counter medications that can be of help in relieving those unpleasant symptoms. For instance, Mucinex recently introduced Mucinex InstaSoothe, a new product line of lozenges and sprays designed to numb, soothe and relieve that sore throat pain. The lozenges contain ingredients like Hexylresorcinol (also known as Hex), a local anesthetic for topical use on the mucous membranes, which helps to deliver that ‘numbing’ effect to throat and mouth, providing that much needed relief. The holiday season adds more to-dos and pressure, causing us to set high expectations and race to accomplish tasks. According to Dr. Caudle, if your energy is low, simply rest and take the time you need to focus on important tasks. Keep those vitamins handy and be sure to fuel your body with the right nutrients to help maintain a healthy immune system. Finally, for those of you back at work or school, be sure to bundle up in the colder weather, wear a mask, wash your hands and remember to continue social distancing. People must use over-the-counter products as directed. If your symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. For more information on how to power through this cold and & flu season, visit Mucinex.com. About Dr. Jennifer Caudle: Dr. Jen Caudle is a board-certified family medicine physician and associate professor in the department of Family Medicine at Rowan University-School of Osteopathic Medicine. She appears regularly as an on-air health expert for local and national news outlets, including ‘The TODAY Show’, CNN, FOX News, PBS, Fox 29 Philadelphia News, and many others. Dr. Jen’s health articles have been published in The Daily Beast, CNN.com, and ABCNews.com, among others. Dr. Jen graduated with honors from Princeton University and earned her medical degree from UMDNJ – School of Osteopathic Medicine. About the Survey*: This random double-opt-in survey of 2,005 Americans was commissioned by Mucinex between August 26 and August 30, 2021. It was conducted by market research company OnePoll, whose team members are members of the Market Research Society and have corporate membership to the American Association for Public Opinion Research ( AAPOR ) and the European Society for Opinion and Marketing Research ( ESOMAR ). About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 09, 2021 05:00 PM Eastern Standard Time

Video

Microban® International Announces a New Range of Antiviral Technologies

Microban International

Microban International, the global leader in antimicrobial solutions, odour control and residual sanitisation/disinfection solutions, is pleased to announce a new range of antiviral technologies that are proven to reduce viral loading on products and surfaces. Microban has long been a trusted partner in a wide range of sectors – from consumer and healthcare to industrial and construction – and this announcement adds to the versatility of the company’s technology portfolio. Microban ® technology can be incorporated into various materials during manufacturing, becoming part of the product’s structure to provide inherent and enduring protection from microbes. Recent data demonstrates that new antiviral technologies from Microban conform to both ISO 18184 – which assesses the antiviral performance of treated textile products, such as woven and knitted fabrics, fibres, yarns, and braids – and ISO 21702, which measures activity in treated plastics and other non-porous surfaces. Thorough testing was performed to evaluate the efficacy of each product type against many viruses, including bacteriophage Phi6, an important surrogate virus for SARS-CoV-2. The results showed that articles treated with these technologies can now benefit from reduced viral loading* by up to 99 %. Antiviral technologies from Microban inhibit the viruses’ ability to remain viable on surfaces. The modes of action vary, disrupting the structure of either the outer protein coat – to prevent viruses from recognising or binding to host cells – or nucleic acid payload, to prevent viral replication. This gives manufacturers a valuable product feature and provides consumers with added peace of mind. Michael Ruby, President of Microban International, explained: “We are excited with the latest results confirming the antiviral activity of our new technologies. Assessing antiviral efficacy in treated products to a standard that meets the complex regulatory landscape is an arduous process, but we have been confident throughout that our innovative solutions conformed to the rigorous ISO standards. Our world-class research team and global in-house regulatory department worked diligently to ensure that the technology is recognised as effective and compliant across various markets, to support partners with their claims and give customers even greater confidence in products protected with Microban antiviral technology.” Following the start of the COVID-19 pandemic, there was a monumental upsurge in demand for antiviral technology in products and it is readily acknowledged that Microban was not the first in the industry to make antiviral claims. Instead, the company invested a considerable amount of time and resources to ensure that its antiviral technologies were not only scientifically proven to be effective in reducing viral loading on surfaces and products, but that they could also be used in a regulatory compliant manner by brands and manufacturers across a variety of territories and product types. Microban is committed to being a reliable and trusted industry leader, and its unrivalled regulatory expertise can help to ensure that partners are aware of the implications that antiviral claims can have on their product types in the countries where they are being sold. For more information on Microban’s new range of antiviral technologies and registration requirements in your territory, visit www.microban.com/antiviral/technologies or contact your Microban representative. *Antiviral efficacy may vary depending on substrate type, application dosage of the treatment, impurities, and application procedure. Only Microban antiviral technologies that are registered with US EPA and are EU BPR compliant are being offered for sale. In the US, antiviral technologies may only be incorporated into products that are or will be registered with the US EPA. Contact your Microban representative for further information. About Microban International: Part of Barr Brands International (BBI), Microban International is home to the most trusted and well-known global brands in the antimicrobial, odour control, and sanitisation / disinfection markets – Microban ® and Ultra-Fresh ®. Our organisation has experienced over 100 collective years of growth and has revolutionised the industry. As the global leader, our proactive systems keep products cleaner, and control odours better by preventing problems before they start. Microban International drives innovation by combining science and creative solutions that enhance high-quality consumer, textile, industrial and medical products around the world. Today, the Microban and Ultra-Fresh brands and our technologies are featured on thousands of products worldwide. The company is headquartered in North Carolina with operations in North America, Europe, and Asia Pacific. For more information, please visit www.microban.com. © 2021 kdm communications limited Editorial contact for further information or follow-up Sarah Khan or Audrey Jestin at kdm communications limited, St Neots, UK Tel. +44 (0) 1480 405333 Fax: +44 (0) 1480 477833 Contact Details kdm communications limited Sarah Khan +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com

November 09, 2021 07:01 AM Eastern Standard Time

Image

VinFuture foundation hosts public dialogue about "Renewable energy & new materials for the future" with Nobel-Winning professor

Vingroup

VinFuture Foundation will hold its Online Science Dialogue series’ second installment discussing “Renewable energy and new materials for the future" on November 12th, 2021. The Dialogue will see the attendance of world-class scientists, most notably Professor Konstantin (Kostya) Sergeevich Novoselov, a Nobel Prize laureate in Physics. The event is aimed at bringing science and technology closer to the general public with solutions that have high real-world applicability. HANOI, VIETNAM - Media OutReach - 8 November 2021 - This November, VinFuture 's Dialogue is titled "Renewable energy and new materials for the future" and centers around foundational knowledge and applications of new energy and materials in humanity's response to the global energy crisis. As part of the program, young scientists will also have chances to converse with world-leading scientists, and to discuss the opportunities and challenges they encounter in their start-ups, thereby bringing research projects into industrial production and out into the world. Most notably, leading the discussion on "Future materials" will be the Nobel Prize laureate in Physics - Professor Konstantin (Kostya) Sergeevich Novoselov. As the youngest scientist to have been awarded the Nobel Prize in Physics since 1973, Prof. Novoselov has a global influence in condensed matter physics and nanotechnology. His achievements with graphene - the strongest ultra-thin material in human knowledge - promise to deeply change the fields of Science and Technology, Industry, and Medicine. Prof. Novoselov is currently a Fellow of the Royal Society, a member of the US National Academy of Science, as well as the National University of Singapore's Tan Chin Tuan Centennial Professor and Director of the Institute for Functional Intelligent Materials. Since 2014, Prof. Kostya Novoselov has always been featured as one of the most cited scientists globally and as part of the world's top 0.01% in the field of Science and Nanotechnology (PLOS, 2021). Professor Nguyen Thuc Quyen, Director for Polymers and Organic Solids, Professor in the Department of Chemistry & Biochemistry at the University of California, Santa Barbara (UCSB), will speak at the Dialogue on the topic of solar energy. With more than 418 research projects and 24 patents on renewable energy, electronic - organic devices, solar cells and photovoltaics, etc., Prof. Thuc Quyen was one of the world's most influential scientific minds and Top 1% Highly Cited Researchers in Materials Science according to Thomson Reuters and Clarivate Analytics for 5 consecutive years, from 2015 to 2019. Dr. Corey Hoven, Founder and CTO of Next Energy Technologies, will bridge the gap between scientific research and practical application. His company has successfully commercialized smart windows that can generate electricity for high-rise buildings using solar energy. VinFuture's Science Dialogue series aims to provide a space for open dialogue with the public, spreading the values of "science at the service of humanity" and contributing to the United Nations' 17 Sustainable Development Goals (SDGs). The Dialogue gives special attention to undergraduates, postgraduates, scientists, and young technology entrepreneurs in Vietnam and around the world. They will have the opportunity to share new perspectives, discuss breakthrough ideas, and raise their concerns about research topics or start-up projects and innovations in order to be discussed and addressed by the guest speakers. Dr. Le Mai Lan, Vice Chairman of Vingroup and Representative of VinFuture Foundation, shared: "Through the public dialogue series, we hope that leading scientists and researchers around the world can share their great contributions to the public in easy-to-understand language, turning science into a familiar and inseparable part of people's lives. At the same time, we would like to inspire youth to take on responsibility for pressing global issues, thereby encouraging them to pursue scientific research to find solutions." Previously, in September 2021, the first dialogue titled "How Science is Changing Global Health?" was successfully organized by VinFuture Foundation with the participation of world-leading scientists in the field of health management, such as Prof. Ezekiel Emanuel (Vice Provost for Global Initiatives at the University of Pennsylvania, USA), Professor Alta Schutte (Principal Theme Lead of Cardiac, Vascular and Metabolic Medicine in the Faculty of Medicine and Health at the University of New South Wales, Sydney, Australia),... All VinFuture webinars will be open to the public free-of-charge via Zoom and Facebook: https://www.facebook.com/VinFuturePrize/ (Language: English). Register to participate in the event here. About VinFuture Foundation VinFuture Foundation is an independent and non-profit foundation operating in Vietnam. It was founded with the vision of creating meaningful changes in people's daily lives through the celebration of global technological innovations. The Foundation's core activity is awarding the annual VinFuture Prize for breakthrough scientific and technological innovations that have made or have the potential to create meaningful changes in people's lives. In addition, the Foundation will conduct many activities to accomplish its mission, such as funding research projects, collaborating in academic development, and promoting STEMM education. https://www.facebook.com/VinFuturePrize/ #VinFuture Contact Details Vingroup v.chidqd@vingroup.net Company Website https://www.vingroup.net/en

November 08, 2021 09:00 AM Eastern Standard Time

Image

1 ... 189 190 191 192 193 ... 235